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A B S T R A C T
To formulate inactivated inﬂuenza vaccines, the concentration of hemagglutinin (HA) must be accurately de-
termined. The standard test currently used to measure HA in inﬂuenza vaccines is the Single Radial
Immunodiﬀusion (SRID) assay.
We developed a very rapid, simple and sensitive alternative quantitative HA assay, namely the Latex
Agglutination Assay (LAA). The LAA uses the Spherotest® technology, which is based on the agglutination of HA-
speciﬁc immunoglobulin-coated latex beads. The amount of HA in a sample is calculated from the level of bead
agglutination by a simple absorbance measurement at 405 nm against a standard curve generated using a
monovalent vaccine standard.
In less than 2 hours, tens of samples could be quantiﬁed using the LAA as opposed to 2 days for the SRID
assay. Ten steps are required to complete an SRID assay as compared to 6 steps for the LAA, from sample
preparation through spectrophotometric analysis. Furthermore, the limit of detection of the LAA was found to be
approximately 15 ng HA/mL, similar to an ELISA, with the quantiﬁcation of less than 1.8 μg HA/mL. The
quantiﬁcation limit of the SRID is usually considered to be approximately 5 μg HA/mL.
The development of the assay and a comparison of the titers obtained by SRID and LAA for several mono-
valent vaccines corresponding to various strains were performed. For A/H5N1 and A/H1N1 monovalent vac-
cines, the LAA was found to be linear and accurate as compared to the SRID. The precision of the LAA was close
to that of the standard test, and good reproducibility from one laboratory to another was observed. Moreover,
the LAA enabled HA quantiﬁcation in AlOOH-adjuvanted and in emulsion-adjuvanted low-dose vaccines as well
as unadjuvanted vaccines.
In conclusion, LAA may be useful to rapidly and accurately measure inﬂuenza HA protein in monovalent
vaccines, especially in those containing less than 5 μg/mL of HA in the presence of an adjuvant.
1. Introduction
Inﬂuenza viruses are negative stranded RNA viruses of the
Orthomyxoviridae family. Three types of inﬂuenza viruses, inﬂuenza A,
B and C, are capable of infecting humans, with inﬂuenza A and B being
the most common circulating types. Inﬂuenza A viruses are classiﬁed
into subtypes based on the antigenic identity of the two major surface
glycoproteins on the virion, hemagglutinin (HA) and neuraminidase
(NA). Both proteins lead to an antibody responses upon infection and
antibodies against HA confer protective immunity (Gomez Lorenzo and
Fenton, 2013), while antibodies against NA reduce severity of disease
by restricting viral replication (Johansson and Cox, 2011).
Global inﬂuenza epidemics emerge seasonally and typically occur
during the winter seasons of the northern and southern hemispheres.
Seasonal inﬂuenza epidemics result annually in 3–5 million cases of
severe illness and 250,000–500,000 deaths worldwide (WHO, 2016).
The emergence of a pandemic H1N1 strain in 2009 (Neumann et al.,
2009) and highly pathogenic avian H5N1 and H7N9 inﬂuenza viruses
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(de Jong et al., 1997; Gao et al., 2013) has reaﬃrmed that inﬂuenza
remains a serious global public health concern. Vaccination is con-
sidered the most eﬀective strategy to reduce the large morbidity and
mortality caused by inﬂuenza infection (Poland et al., 2001; Zambon,
1999).
Current seasonal approved-vaccines are composed of either triva-
lent or quadrivalent mixtures of the most globally-prevalent circulating
inﬂuenza strains (A/H1, A/H3 and B). Many of these vaccines are
produced in embryonated chicken eggs, harvested and processed into
either live attenuated, or more commonly, inactivated viral vaccine
preparations. The alternatives to egg-based production systems are cell
culture-based systems and recombinant inﬂuenza antigens. The Food
and Drug Administration (FDA) has approved two such vaccines in
2012 and 2013, respectively: Flucelvax (Seqirus), produced in Madin-
Darby Canine Kidney (MDCK) cells and Flublok (Protein Sciences
Corporation), the ﬁrst approved vaccine made of recombinant proteins
produced in insect cells.
All these vaccines have to be reformulated every year due to the
antigenic drift, ie mutations in surface glycoproteins, responsible for
immune escape. Inﬂuenza virus also can undergo antigenic shift due to
the reassortment of genomic segments of at least two diﬀerent subtypes
of inﬂuenza A viruses, which can result in an inﬂuenza pandemic. The
2009 inﬂuenza pandemic occurred when an A/H1N1 virus emerged
from a triple-reassortant containing genes from avian, human, and
swine inﬂuenza viruses (Michaelis et al., 2009). During this pandemic,
several adjuvanted and unadjuvanted vaccines were developed. The
adjuvanted vaccines contained a reduced amount of antigen per dose to
increase the manufacturing capacities for the worldwide vaccine supply
(Abelin et al., 2011). In addition to H1N1 vaccines, several candidate
pre-pandemic H5N1 mock-up vaccines have been produced in the past
with the aim of accelerating the regulatory processes for licensure of
these vaccines in case of a H5N1 pandemic.
For vaccine formulation, release, and stability testing, the major
antigenic envelope protein, HA, must be accurately quantiﬁed. The
“gold standard” test used to determine HA in inactivated inﬂuenza
vaccines is the Single-Radial ImmunoDiﬀusion (SRID) assay. This
modiﬁed Ouchterlony technique is based on immunodiﬀusion of the
antigen into an agarose gel containing a speciﬁc anti-serum (Schild
et al., 1975; Wood et al., 1977). New HA reference antigens and anti-
sera are prepared and calibrated by the Essential Regulatory Labora-
tories (ERL) each time a new virus strain is introduced into the vac-
cines. This calibration is described by the Word Health Organization
(WHO, 2012). SRID has been used for inﬂuenza vaccine manufacturing
for almost four decades. SRID has replaced less reliable tests, which
were based on HA-induced aggregation of erythrocytes (Schild et al.,
1975). Correlation has been demonstrated between SRID-measured
vaccine potency and vaccine immunogenicity in clinical trials (Cate
et al., 1983; Hobson et al., 1972; Wright et al., 1983).
While the SRID is the reference assay accepted by regulatory
agencies to assess HA content and potency in inﬂuenza vaccines, the
technique is very time consuming with at least 10 manual steps con-
ducted over 2 days, from the preparation of the plates and agarose gel
to the plate staining and ring readings (Fig. 1). In terms of sensitivity,
the limit of quantiﬁcation is typically evaluated to be approximately
5 μg/mL for unadjuvanted monovalent inﬂuenza vaccines. Further-
more, when HA concentration is measured in monovalent vaccines
adjuvanted with aluminum salt-based adjuvants (i.e., AlOOH) by SRID,
complex pre-treatments are required to desorb the HA antigen from the
adjuvant (Sizer et al., 2014). SRID is also diﬃcult to apply to emulsion-
adjuvanted inﬂuenza vaccines due to interference with the diﬀusion of
the antigen in the agarose gel. Therefore, alternatives to the standard
SRID assay needed to better quantify HA in adjuvanted inﬂuenza pan-
demic vaccines, which may contain as little as 1.9 μg of HA/dose
(Schubert, 2009).
In this context, we developed a simple, sensitive and rapid alter-
native assay, the Latex Agglutination Assay (LAA) to determine the
concentration of HA in low-dose adjuvanted vaccines. This new ana-
lytical method can be used on a routine basis to quantify samples within
two hours (Fig. 1).
2. Materials and methods
2.1. Monovalent inﬂuenza vaccines tested by LAA
Monovalent inﬂuenza vaccines corresponding to strains A/New
Caledonia/20/99 (H1N1), A/Wisconsin/67/2005 (H3N2), B/Malaysia/
2506/2004, A/Vietnam/1194/04 (H5N1) NIBRG-14, A/Indonesia/05/
05 (H5N1) NIBRG-2 or A/California/07/09 (H1N1) were prepared
following the traditional embryonated egg production process in Sanoﬁ
Pasteur (Val de Reuil, France) from the reference master seed lots given
to the vaccine manufacturers by the National Institute for Biological
Standards and control (NIBSC, Potters Bar, UK) or the Center for
Disease Control (CDC, Atlanta, US). Various adjuvanted inﬂuenza vac-
cines were also analyzed in this study: the A/California/07/09 (H1N1)
adjuvanted with AF03, a squalene emulsion, the A/Vietnam/1194/04
(H5N1) NIBRG-14 and the A/Indonesia/05/05 (H5N1) NIBRG-2 ad-
juvanted with AlOOH or AF03.
2.2. Reference reagents used in LAA
SRID reference sheep antisera were used to coat the beads: A/New
Caledonia/20/99 NIBSC code 04/260, A/Wisconsin/67/2005 NIBSC
code 05/174, B/Malaysia/2506/04 NIBSC code 05/236, A/Vietnam/
1194/04 (H5N1) NIBRG-14 NIBSC code 05/204, A/Indonesia/05/05
(H5N1) NIBRG-2 NIBSC code 03/212 or A/California/7/2009-like
NIBSC code 09/194.
2.3. Principle of the LAA
The principle of the Spherotest® is described in Fig. 2. Brieﬂy, when
the anti-HA antibody-coated beads were mixed with a sample con-
taining inﬂuenza vaccine, their aggregation with the HA causes a de-
crease of light absorption at an optical density (OD) of 405 nm. The OD
is inversely proportional of the HA quantity.
2.4. Preparation of the beads
Optically active R9331 latex beads from Indicia Biotechnology
(Saint Genis l'Argentière, France) with a diameter of 0.741 μm were
used. Strain speciﬁc anti-sera were puriﬁed on a protein G column and
puriﬁed IgGs were adsorbed passively onto the beads or linked cova-
lently to them. Various amount of puriﬁed IgGs per gram of beads were
assessed.
2.5. Zwittergent treatment
Inﬂuenza monovalent vaccine samples were treated with 0.01, 0.05
or 0.1% (W/V) of Zwittergent 3–14 (Calbiochem, Merck, Fontenay sous
Bois, France). For this purpose 50 μL of the sample were mixed with
50 μL of 0.1, 0.5 or 1% (W/V) of Zwittergent 3–14 in 400 μL of the bead
dilution buﬀer containing phosphate buﬀer pH 7.4, 0.1 mg/mL bovine
serum albumin and 0.9% sodium azide. The mixture was then in-
cubated 30 min at room temperature (RT).
2.6. Development of the LAA
A volume of 100 μL of the 10-fold diluted monovalent vaccines
prepared previously was loaded in the ﬁrst well of the ﬁrst column of a
96-well plate. Two-fold serial dilutions were then performed in the bead
dilution buﬀer. The reference (a monovalent vaccine of the same strain
titrated in SRID), a positive control (another monovalent vaccine of the
same strain titrated by SRID) and a negative control (beads with
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dilution buﬀer) were also 2-fold serially diluted and added to each
plate.
Antibody-coated beads were extemporaneously diluted 1:4 with the
bead dilution buﬀer and were homogenized by vigorous stirring for at
least 60 s just before dispensing.
A volume of 20 μL of the diluted beads was then added into each
wells of a new 96-well ﬂat bottom microplate. Another 20 μL of each
sample dilution previously prepared was then added to the beads. The
plate was agitated on a microplate shaker for 5 min at RT at a speed of
1000 revolutions per minute (rpm). A volume of 100 μL of the stopping
buﬀer (containing 15 mM NaCl and 0.1% tween) was added in each
well and the plate was shaken for another 5 min at 600 rpm.
The optical density was immediately measured at 405 nm with a
microplate spectrophotometer (e.g. Versamax, Molecular Devices,
Sunnyvale, CA, USA).
The monovalent vaccine previously titered by SRID was used as a
reference. The relationship between the reported optical density and
the corresponding reciprocal standard dilution was modeled as a 4-
parameter regression with Softmax pro (Molecular Devices, St Grégoire,
France). The HA concentrations of the test samples, including the in-
ternal positive control, were calculated using the reference curve.
2.7. SRID
The SRID assay for determining the HA content of the diﬀerent un-
adjuvanted monovalent samples was performed as described previously
Fig. 1. Description of the various steps and approx-
imate duration of the SRID and LAA techniques.
Fig. 2. Principle of the Spherotest®.
Single non-agglutinated submicron microspheres present a maximum
of absorption at their OD max which depends on the refractive indices
of both microspheres and environmental buﬀer, and on the diameter
of the microspheres. Therefore, the decrease of the number of single
microspheres can be optically monitored and quantiﬁed. In contact
with the antigen, sensitized microspheres agglutinate to form clusters
of bigger apparent diameter where they do not absorb at the same OD
max.
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(Legastelois et al., 2011) as adapted from Schild et al. (1975) and Wood
et al. (1977). Brieﬂy, the samples were ﬁrst incubated with 1% (w/v)
Zwittergent 3–14 for 30 min at room temperature (RT) and subjected to
immunodiﬀusion for approximately 20 h (h) at RT in an antibody-loaded
agarose gel. The diameters of the precipitation rings of antigen–antibody
complexes were measured utilizing an Epson Professional scanner 1680
(Microvision, Evry, France). The ﬁnal titers were calculated from the cali-
bration curve of a reference whole virus batch preparation of known HA
concentration obtained from the NIBSC, using the Immulab 4.2 software.
Each sample was titrated at least three times on three dilutions. Under these
conditions, the precision of the SRID is estimated to be x/1.2 with a range of
quantiﬁcation of ∼5–30 μg HA/mL.
2.8. Assessment of the analytical performance parameters
2.8.1. Linearity
Three separate series were performed by two operators on diﬀerent
days. Each run included the assay of a range of 5 or 6 concentrations of
HA respectively for the AF03-adjuvanted A/California/07/09 (H1N1)
vaccine and the unadjuvanted and AF03-adjuvanted A/Vietnam/1194/
04 (H5N1) NIBRG-14 vaccines. For each vaccine, the SRID titers were
known and independent dilutions were performed. The theoretical ex-
pected concentration was calculated for each dilution level.
The linearity over the chosen range was tested through the fol-
lowing steps: i) the homogeneity of bound variances was veriﬁed by
COCHRAN’s test, ii) the dependence between the theoretical expected
concentration measured and the linearity of this relation was tested
using an unweighted linear regression using least squares method. A
signiﬁcant slope (p-value< 0.01) and non-signiﬁcant deviation from
linearity must be demonstrated (p-value> 0.05).
The limit of quantiﬁcation was deﬁned as the lower concentration of
the linearity domain.
2.8.2. Accuracy
Accuracy was obtained from the equation: % of recovery = (ob-
served concentration/theoretical expected concentration)*100, i.e. by
calculating all recovery percentages obtained between the observed
concentrations measured in LAA and the theoretical expected con-
centrations related to SRID from the same samples and the same ex-
perimental design used in the linearity study.
The method was considered accurate if all recovery percentages are
included within the equivalence limits [80%; 120%].
2.8.3. Precision
The precision is evaluated through repeatability (intra-assay) and
intermediate precision (inter-assay). Three independent runs in inter-
mediate precision conditions, each including three independent mea-
surements in repeatability conditions were performed to assess both
parameters. For the A/Vietnam/1194/04 (H5N1) NIBRG-14 vaccines,
various concentrations were tested: 60 μg HA/mL for the AlOOH-ad-
juvanted vaccines and 3.8, 15 and 50.9 μg HA/mL for the unadjuvanted
and AF03-adjuvanted vaccines. For the AF03-adjuvanted A/California/
07/09 (H1N1) vaccine, both 7.6 and 15 μg HA/mL concentrations were
tested. The precision was expressed as the 95% conﬁdence interval of
intermediate precision for one run with one measurement.
2.8.4. Inter-laboratory reproducibility
A comparison between the results of two independent laboratories A
and B (two diﬀerent operators, two diﬀerent lab facilities) was per-
formed with the A/Indonesia/05/05 (H5N1) NIBRG-2 strain un-
adjuvanted or adjuvanted with AF03 or AlOOH. The three samples were
titrated in two separate series of six replicates. The accuracy is de-
termined by the percentage of recovery calculated between the means
of the HA concentrations determined for the two independent labora-
tories. The F-test and t-test were performed respectively on the variance
and the mean of the concentrations.
2.8.5. Statistical analyses
All the statistical processing was performed under SAS v9.1 software
(SAS Institute Inc, USA).
In order to obtain a normal distribution of the data, a logarithmic
transformation was applied to the titers.
3. Results
3.1. Development of the LAA
The development of the LAA was mainly performed following the
supplier recommendation with some optimizations. First, two types of
binding on beads of the IgGs puriﬁed from the reference NIBSC sera
were evaluated, a passive adsorption and a covalent adsorption. For
each type of binding, two amounts of antibodies were tested: 20 and
40 mg per gram of beads. This optimization was carried out using
beads-coated with three reference epidemic strain serums: A/New
Caledonia/20/99 (H1N1), A/Wisconsin/67/2005 (H3N2) and B/
Malaysia/2506/2004. The choice of the type of beads was based on the
best agglutination percentage between beads and antigen traduced by
the highest OD diﬀerence between the negative and the positive con-
trol.
The best result was obtained with 40 mg of puriﬁed anti-serum per
gram of beads, passively adsorbed (data not shown). Moreover, the
volume of the reaction was also optimized: 20, 50, 100 μL of beads and
20, 50 100 μL of Ag were assessed, as the lower the reaction volume,
the shorter the incubation time will be. Finally 20 μL of beads and 20 μL
of antigen were chosen.
Various concentrations of Zwittergent 3–14 0.1, 0.05 and 0.01%
were then tested using the A/Indonesia/05/05 (H5N1) NIBRG-2
monovalent vaccine samples adjuvanted or not with AlOOH (Table 1).
One percent Zwittergent 3–14 is currently used in the SRID assay to
disrupt the virions and solubilize the viral HA proteins anchored in the
lipid envelope to allow the quantiﬁcation of the HA. It is also used to
separate viral proteins from the AlOOH adjuvant (Sizer et al., 2014).
The optimal concentration of Zwittergent used to obtain highly re-
producible LAA titers and accurate quantiﬁcation of AlOOH adjuvanted
monovalent vaccine was 0.01%. Higher concentrations of detergent
(0.1 and 0.05%) resulted in complete inhibition of agglutination. The
reference monovalent and the positive control corresponding to each
inﬂuenza strain were also treated with 0.01% Zwittergent before
quantiﬁcation.
A LAA representative graph for the unadjuvanted A/Vietnam/1194/
044(H5N1) NIBRG-14 monovalent vaccine, after LAA optimization, is
presented in Fig. 3.
Table 1
HA quantiﬁcation by LAA in A/Indonesia/05/05 (H5N1) NIBRG-2 vaccine samples ad-
juvanted or not with AlOOH using various% of Zwittergent 3–14.
% Zwittergent
3–14
Bead agglutination
with antigen
LAA titer μg/mL LAA titer μg/
mL
H5N1 vaccine
unadjuvanted
(143 μg/mL in SRID)
H5N1 vaccine
AlOOH (70 μg/
mL in SRID)
0.1 – * *
0.05 – * *
0.01 +++ 165 72
0 +++ 123 16
The SRID concentrations are given for each vaccine in brackets.
An estimation of the agglutination of the beads is also shown.
–: No bead agglutination.
+++: Bead agglutination.
*: No titer
Bold letters: optimal concentration of Zwittergent.
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3.2. HA quantiﬁcation in diﬀerent inﬂuenza monovalent vaccines
After the development of the LAA, the HA quantiﬁcation in several
inﬂuenza monovalent vaccines was estimated by this method and
compared to the reference assay, SRID. As shown in Table 2, the LAA
titers obtained were very close to the SRID titers with a ratio (SRID
titer/LAA titer) between 0.87 and 0.99. The limit of detection was also
assessed for various monovalent vaccines. As expected for such assays,
the limit of detection was very low and could detect as little as 15 ng
HA/mL (data not shown).
These results showed that the LAA could be considered as an al-
ternative technique to SRID for HA quantitation and the performance
parameters were next evaluated.
3.3. Assessment of the analytical performance parameters
3.3.1. Linearity of LAA
LAA was linear on the tested dose ranges between 1.8–50.9 μg HA/
mL for the AF03-adjuvanted and unadjuvanted A/Vietnam/1194/04
(H5N1) NIBRG-14 vaccines (Fig. 4). LAA was linear between
3.4–43.8 μg HA/mL for the AF03-adjuvanted A/California/07/09
(H1N1) vaccine (data not shown). All acceptance criteria were satisﬁed.
The limit of quantiﬁcation was deﬁned as the lowest concentration of
the linearity domain: 1.8 μg HA/mL for the AF03-adjuvanted and un-
adjuvanted A/Vietnam/1194/04 (H5N1) NIBRG-14 vaccines and 3.4 μg
HA/mL for the AF03-adjuvanted A/California/07/09 (H1N1) vaccine.
These results conﬁrmed that the quantiﬁcation limit of the LAA method is
lower than the SRID method, which in our hands is approximately 5 μg. HA
concentrations below 1.8 μg HA/mL were intentionally not tested since
inﬂuenza vaccines do not contain less than 1.8 μg HA/mL.
3.3.2. Accuracy of LAA
For each concentrations tested, the recovery percentage between
the obtained concentrations in LAA and the respective expected con-
centrations determined by SRID was between 80 and 120%. It was
concluded that the LAA was accurate from 1.8 to 50.9 μg HA/mL for the
AF03-adjuvanted and unadjuvanted A/Vietnam/1194/04 (H5N1)
NIBRG-14 vaccines (Fig. 5). Accuracy of the LAA was also conﬁrmed for
the AF03-adjuvanted A/California/07/09 (H1N1) vaccine with a global
mean percent recovery of 91%.
3.3.3. Precision of LAA
For both pandemic vaccines, A/California/07/09 (H1N1) and A/
Vietnam/1194/04 (H5N1), the intermediate precision of the LAA
evaluated for one run and one measurement was lower than the SRID
assay precision: x/1.2 for the SRID, more than x/1.3 for the LAA.
However, when three independent experiments were performed, the
LAA precision was similar to the SRID (Table 3).
3.3.4. Inter-laboratory reproducibility
The reproducibility was performed on another pandemic vaccine,
namely the A/Indonesia/05/05 (H5N1) vaccine previously tested un-
adjuvanted in Tables 1 and 2. For each A/Indonesia/05/05 (H5N1)
vaccine (unadjuvanted, AlOOH or AF03-adjuvanted), the percentages
of recovery calculated between the means of the 12 HA concentrations
determined by two independent laboratories were all included between
80% and 120% (Table 4). The F-test and t-test showed no signiﬁcant
diﬀerence between the two laboratories concerning respectively, the
variance and the mean of the concentrations. These data indicate that
the LAA is reproducible with similar results obtained in diﬀerent la-
boratories.
4. Discussion
The reference SRID assay used to determine HA content in inﬂuenza
vaccines is labor intensive and time consuming. The present study was
conducted to develop a simple, sensitive and rapid alternative assay
method that could be used on a routine basis to quantify inﬂuenza
vaccine samples within two hours. Unlike other latex bead agglutina-
tion assays previously described for detecting inﬂuenza viruses (Chen
et al., 2007), the LAA presented here is based on the Spherotest®
technology, which produced accurate HA quantiﬁcation of seasonal and
pandemic monovalent vaccines.
The qualiﬁcation study performed demonstrated that the LAA is
suitable to quantify HA as the LAA method is linear, accurate when
compared to SRID. The precision is close to that of the SRID assay with
a limit of quantiﬁcation lower than that of SRID. Furthermore, the LAA
was found to be reproducible from one laboratory to another.
Moreover, LAA appears to quantify HA in its native conformation. To
demonstrate this, complementary studies were performed using
monovalent inﬂuenza vaccine samples submitted to heat degradation
showing a decrease of HA titers measured by LAA (data not shown).
These results are of interest since change of HA conformation has been
shown to result in a loss of immunogenicity (Minor, 2015; Williams,
1993) and cannot be assessed with other methods such as HPLC and
mass spectrometry.
During the LAA development, its speciﬁcity was also assessed. It was
observed that the IgGs puriﬁed from the polyclonal reference sera used
to coat the beads could recognize other strains probably due to the
sensitivity of the LAA (data not shown). Hence, the method was mainly
developed for monovalent pandemic vaccines and cannot be used to
quantify each monovalent in a trivalent or quadrivalent vaccine.
One particular feature of the LAA is the determination of the
amount of HA in low-dose adjuvanted inﬂuenza vaccines. The AlOOH
or AF03 adjuvants have been used to formulate A/H5N1 inﬂuenza
vaccines (Bresson et al., 2006; Levie et al., 2008). Given that A/H5N1
vaccines were shown to not be as immunogenic in humans as seasonal A
Fig. 3. Graph of OD values at 405 nm against HA concentrations for the unadjuvanted A/
Vietnam/1194/04 (H5N1) NIBRG-14 monovalent vaccine after optimization of the LAA
technique.
Vaccine was at 1/10 dilution in the ﬁrst well followed by serial twofold dilutions. Data
are representative of at least three independent experiments. Each point in this curve is a
mean ± standard error of mean.
Table 2
HA quantiﬁcation by LAA in various monovalent vaccines.
Monovalent vaccine SRID titer
(μg/mL)
LAA titer
(μg/mL)
Ratio SRID titer/
LAA titer
A/NC/20/99 (H1N1) 119.9 130.5 0.92
A/Wisconsin/67/05 (H3N2) 141.0 158.4 0.89
B/Malaysia/2506/04 130.0 131.5 0.99
A/California/07/09 (H1N1) 15.0 16.9 0.89
A/Vietnam/1194/04 (H5N1)
NIBRG-14
101.8 102.8 0.99
A/Indonesia/05/05 (H5N1)
NIBRG-2
143.0 165.0 0.87
A ratio between the titers of the two assays is mentioned.
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inﬂuenza strain vaccines, probably due to the absence of subtype-spe-
ciﬁc immune priming, inﬂuenza vaccine producers have primarily fo-
cused on the preparation of adjuvanted vaccines to increase vaccine
immunogenicity, to induce cross-strain reactive antibodies and to re-
duce the vaccine dose (Keitel and Atmar, 2009). The same approach
was taken during the 2009 A/H1N1 pandemic, except that this pan-
demic strain appeared to be as immunogenic as the seasonal A inﬂuenza
strains. Hence the role of the adjuvant was essentially for antigen dose
sparing in this case (Schubert, 2009). Our results suggest that the LAA
could be used to quantify the amount of HA in vaccine batches ad-
juvanted with AlOOH or AF03 as eﬃciently as in unadjuvanted vaccine.
For emulsion-based adjuvanted vaccines, it has been shown that a
dose of 1.9 μg of HA (3.8 μg/mL) is suﬃcient to induce a protective
immunogenicity even though the trivalent or quadrivalent epidemic
vaccines are formulated at 15 μg of HA of each strain per dose without
adjuvant (SAGE Working Group, 2009; Vogel et al., 2009). SRID, with
quantiﬁcation limit around 5 μg HA/mL, is not an ideal assay for the
determination of HA in the low-dose pandemic vaccines. In contrast,
LAA can accurately measure low doses of HA contained in these vac-
cines, since the limit of quantiﬁcation of the LAA was determined at
around 2–3 μg of HA/mL (not tested below) and the sensitivity around
15 ng of HA/mL for the adjuvanted and unadjuvanted monovalent
vaccines.
The SRID assay similarly to the LAA described here, relies on the
availability of reference materials i.e. the HA antigen reference and
corresponding anti-serum. These reagents are updated and distributed
annually by the ERL. It takes in general 2–3 months to prepare and
calibrate them. During a pandemic inﬂuenza situation, the lack of
availability of the reference materials would slow down vaccine de-
velopment. Other antibodies than the puriﬁed IgGs from the reference
anti-serum could be coated on the latex beads as universal antibodies,
e.g., IgM monoclonal antibodies which recognize all the HA subtypes in
egg-derived vaccines (Legastelois et al., 2011), cross-reactive antibodies
directed to the HA stalk region (Ekiert et al., 2011; Hufton et al., 2014),
universal antibodies recognizing non-conformational epitopes (Chun
et al., 2008) or fetuin/lectins mimicking inﬂuenza receptors (Hashem
et al., 2013; Mandenius et al., 2008).
A number of alternative assays to SRID have been suggested. High-
performance liquid chromatography (HPLC) (Lorbetskie et al., 2011)
and mass spectrometry (Creskey et al., 2012; Getie-Kebtie et al., 2013)
have been proposed for HA quantiﬁcation.
Surface plasmon resonance (SPR) has also been developed to
Fig. 4. Linearity between the observed concentra-
tions obtained in LAA compared to the theoretical
expected concentrations obtained in SRID for the
AF03-adjuvanted and unadjuvanted A/Vietnam/
1194/04 (H5N1) NIBRG-14 vaccines.
The linearity was tested on the dose ranges between
1.8–50.9 μg HA/mL for the AF03-adjuvanted and
unadjuvanted A/Vietnam/1194/04 (H5N1) NIBRG-
14 vaccines.
Fig. 5. Accuracy of the LAA for the AF03-adjuvanted
and unadjuvanted A/Vietnam/1194/04 (H5N1)
NIBG14 vaccines: Recovery percentages compared to
the SRID.
The method was considered accurate if all recovery
percentages are included within the equivalence
limits [80%; 120%].
Table 3
Precision of the LAA.
Monovalent vaccine Adjuvant Intermediate
Precision (fold)
Repeatability (fold)
For 1
measurement
For 3 independent
measurements
A/California/07/09
(H1N1)
AF03 0.11 (x/1.30) NDa
A/Vietnam/1194/04
(H5N1) NIBRG-
14
No adjuvant
or AF03
0.15 (x/1.41) 0.09 (x/1.22)
AlOOH 0.14 (x/1.38) 0.08 (x/1.2)
The precision was evaluated through intermediate precision (inter-assay) and repeat-
ability (intra-assay). Three independent runs in intermediate precision conditions, each
including three independent measurements in repeatability conditions were performed to
assess both parameters.
a Not determined.
Table 4
Inter-laboratory reproducibility of the LAA.
Strain Adjuvant Percentage of Recovery
A/Indonesia/05/05 (H5N1) NIBRG-2 No adjuvant 96%
AlOOH 101%
AF03 98%
Accuracy was determined by the percentage of recovery calculated between the means of
the HA concentrations determined for two independent laboratories. The three samples
were titrated in two separate series of six replicates.
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quantify HA in the inﬂuenza vaccines. Some investigators have de-
signed SPR assays using lectins as sensor ligands but such assays are not
strain speciﬁc (Jiang and Eichelberger, 2015; Mandenius et al., 2008).
Another group has developed a method of HA quantitation via an in-
hibition assay using HA proteins for H1N1, H3N2 and B strains im-
mobilized on a sensor chip (Nilsson et al., 2010). All these methods
require complex and expensive instrumentation and highly trained
personnel, which is not the case for the LAA.
Another antibody-based method has been designed, the VaxArray™.
The VaxArray™ Inﬂuenza potency assay is a multiplexed immunoassay
for rapidly quantifying HA in seasonal inﬂuenza vaccines for potency
determination. The assay is based on a “universal” panel of subtype-
speciﬁc monoclonal antibodies printed in an array format. However,
the assay requires a speciﬁc microarray reader, associated lab ware and
a calibration of the reference (Kuck et al., 2017).
Various Enzyme-Linked ImmunoSorbent Assays (ELISA) for mea-
suring vaccine HA concentration have been proposed (Bodle et al.,
2013; Chun et al., 2008; Hashem et al., 2013; Legastelois et al., 2011).
In theory, all these ELISA-based methods described in the literature
could potentially be adapted to the LAA. An advantage of the LAA,
compared to classical ELISA, is that the recognition between the HA in
the vaccine and the beads occurs in suspension, allowing a better in-
teraction between antigen and anti-serum.
Today all these alternatives technologies especially mass spectro-
metry and SPR are presented as potential candidates to replace SRID,
with collaborative studies conducted by several vaccine manufacturers
and ERLs through potency assay working groups (NIBSC, 2017).
We believe that LAA may be useful to rapidly and accurately
quantify the inﬂuenza HA protein in monovalent vaccines especially in
those containing less than 5 μg/mL of HA in the presence of an ad-
juvant. Application of the LAA for the quantiﬁcation of recombinant HA
proteins or Virus like particles produced in various expression systems,
are currently being evaluated. Development of this assay to determine
HA production yields as an industrial process monitoring test is en-
visaged as well.
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